Saad Usmani to Neurotoxicity Syndromes
This is a "connection" page, showing publications Saad Usmani has written about Neurotoxicity Syndromes.
Connection Strength
0.334
-
Jurgens EM, Mitra S, Herrera K, Nemirovsky D, Bready B, Derkach A, Hosszu K, McAvoy D, Firestone RS, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Merz M, Maura F, Giralt SA, Shah GL, Landau HJ, Scordo M, Kotchetkov IS, Santomasso BD, Park J, Leslie CS, Usmani SZ, Perica K, Mailankody S. Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma. Sci Transl Med. 2026 Jul 29; 18(860):eaed0039.
Score: 0.242
-
Htut M, Dhakal B, Cohen AD, Martin T, Berdeja JG, Usmani SZ, Agha M, Jackson CC, Madduri D, Deraedt W, Zudaire E, Yeh TM, Xu X, Pacaud L, Akram M, Jagannath S. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 12; 23(12):882-888.
Score: 0.049
-
van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021 Jun; 8(6):e446-e461.
Score: 0.042